THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFUSION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

被引：2
|
作者：
Wang, Z. [1 ]
Sorror, M. L. [1 ,2 ]
Leisenring, W. [1 ,3 ]
Schoch, G. [1 ]
Maloney, D. [1 ,2 ]
Sandmaier, B. M. [1 ,2 ]
Storb, R. [1 ,2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.323
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
281
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [21] Immunoadsorption in Hematopoietic Stem Cell Transplantation with Major ABO Incompatibility
    Crysandt, Martina
    Jennes, Eva
    Strathmann, Klaus
    Kunter, Uta
    Wilop, Stefan
    Silling, Gerda
    Bruemmendorf, Tim H.
    Beier, Fabian
    Jost, Edgar
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 615 - 615
  • [22] Implications of ABO incompatibility in Allogeneic Hematopoietic Stem Cell Transplantation
    Raturi, Manish
    Das, Kunal
    Kala, Mansi
    Kusum, Anuradha
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 231 - 231
  • [23] Transfusion burden following reduced intensity allogeneic hematopoietic cell transplantation: Impact of donor type
    Subramanian, Sitalakshmi
    Cohn, Claudia
    DeFor, Todd
    Welbig, Julie
    Brunstein, Claudio
    El Jurdi, Najla
    Weisdorf, Daniel
    TRANSFUSION, 2021, 61 (07) : 2064 - 2074
  • [24] Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation
    Atilla, P. Ataca
    Akkus, E.
    Atilla, E.
    Gokmen, N.
    Bozdag, S. Civriz
    Toprak, S. Kocak
    Yuksel, M. Kurt
    Ozcan, M.
    Demirer, T.
    Ilhan, O.
    Beksac, M.
    Akan, H.
    Arslan, O.
    Topcuoglu, P.
    Gurman, G.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2020, 27 (03) : 115 - 121
  • [25] Transfusion requirements after bone marrow transplantation from HLA-identical siblings: The effect of donor-recipient ABO incompatibility.
    Mehta, J
    Singhal, S
    Powles, R
    Horton, C
    Milan, S
    Treleaven, J
    BLOOD, 1995, 86 (10) : 3823 - 3823
  • [26] Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years
    Sorror, Mohamed L.
    Storer, Barry
    Sandmaier, Brenda M.
    Maloney, David G.
    Franke, Georg
    Shizuru, Judith
    Chauncey, Thomas
    Agura, Edward
    Maziarz, Richard T.
    Sahebi, Firoozeh
    Langston, Amelia A.
    Wade, James C.
    Maris, Michael
    Bruno, Benedetto
    Yeager, Andrew M.
    Pulsipher, Michael
    Petersen, Finn
    Bethge, Wolfgang A.
    McSweeney, Peter A.
    Niederwieser, Dietger
    Blume, Karl G.
    Storb, Rainer F.
    BLOOD, 2008, 112 (11) : 753 - 754
  • [27] Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)
    Jacobson, Pamala A.
    Long, Janel R.
    Rogosheske, John
    Green, Kathleen
    Brunstein, Claudio
    Wagner, John E.
    Cao, Qing
    Miller, Jeffrey S.
    McGlave, Philip
    Weisdorf, Daniel
    BLOOD, 2008, 112 (11) : 295 - 296
  • [28] Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation
    Giaccone, L
    McCune, JS
    Maris, MB
    Gooley, TA
    Sandmaier, BM
    Slattery, JT
    Cole, S
    Nash, RA
    Storb, RF
    Georges, GE
    BLOOD, 2005, 106 (13) : 4381 - 4388
  • [29] Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma.
    Maris, MB
    Sandmaier, BM
    Storer, B
    Agora, E
    Wade, J
    Maziarz, RT
    Forman, S
    Shizuru, J
    Chauncey, T
    Kahl, C
    Langston, AA
    Niederwieser, D
    Storb, R
    Maloney, DG
    BLOOD, 2005, 106 (11) : 329A - 329A
  • [30] Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using Pentostatin and donor lymphocyte infusion (DLI).
    Sandmaier, BM
    Maloney, DG
    Maris, MB
    Chauncey, TR
    Pulsipher, M
    Bethge, W
    Little, MT
    Storb, R
    BLOOD, 2004, 104 (11) : 57A - 57A
12345